

**PATENT** 

Customer No. 22,852

Attorney Docket No.: 01142.0122

Group Art Unit: 1646

Examiner: M. PAK

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:		

PAUSCH, Mark H. et al.

Application No.: 08/816,011

Filed: March 11, 1997

For: POTASSIUM CHANNELS, NUCLEOTIDE)

SEQUENCES ENCODING THEM, AND

METHODS OF USING SAME

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## STATEMENT TO SUPPORT FILING AND SUBMISSION UNDER 37 C.F.R. §§1.821 - 1.825

Applicants submit the enclosed substitute copy of the Sequence Listing to correct an inadvertent error. It has come to Applicants' attention that the revised Sequence Listing indicates that the amino acid sequence of SEQ ID NO:4 is encoded by a nucleotide sequence isolated from *D. melanogaster*. In fact, the sequence should be identified as an amino acid sequence encoded by a nucleotide sequence isolated from the species *C. elegans*. This is supported by page 40 of the specification. Please substitute the enclosed Sequence Listing for the Sequence Listing submitted October 15, 2001, and place the enclosed computer readable form of the Sequence Listing into the file.

In connection with the Substitute Sequence Listing submitted herewith, the undersigned hereby states that:

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Customer No. 22,852 Attorney Docket No.: 01142.0114 Application No.: 09/503,849

1. The submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not contain any new matter;

- 2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- 3. All statements made herein on the undersigned's knowledge are true, and all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Antigone G. Kriss

Reg. No. 47,721

(202) 408-4464 (phone)

(202) 408-4400 (facsimile) antigone.kriss@finnegan.com

FINNEGAN **HENDERSON** FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Date: March 12, 2003